State Street SPDR S&P Biotech ETF
525 hedge funds and large institutions have $9.39B invested in State Street SPDR S&P Biotech ETF in 2020 Q2 according to their latest regulatory filings, with 127 funds opening new positions, 187 increasing their positions, 127 reducing their positions, and 55 closing their positions.
131% more first-time investments, than exits
New positions opened: 127 | Existing positions closed: 55
47% more repeat investments, than reductions
Existing positions increased: 187 | Existing positions reduced: 127
26% more capital invested
Capital invested by funds: $7.43B → $9.39B (+$1.96B)
20% more funds holding in top 10
Funds holding in top 10: 15 → 18 (+3)
15% more funds holding
Funds holding: 458 → 525 (+67)
41.76% less ownership
Funds ownership: 211.45% → 169.68% (-42%)
65% less call options, than puts
Call options by funds: $1.13B | Put options by funds: $3.24B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DFO
Duquesne Family Office
New York
|
+$108M |
| 2 |
JP Morgan Chase
New York
|
+$71.1M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$30.2M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$24.8M |
| 5 |
WKKFT
W.K. Kellogg Foundation Trust
Battle Creek,
Michigan
|
+$24.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$250M |
| 2 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$199M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$189M |
| 4 |
N
Natixis
Paris,
France
|
-$155M |
| 5 |
Morgan Stanley
New York
|
-$144M |
XBI Hedge Fund Activity: Q2 2020 in Review
525 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2020, worth a combined $9.39B — up 26% from $7.43B a quarter earlier.
Buyers outnumbered sellers: 127 funds opened new XBI positions and 55 closed out — a net gain of 72 holders — while 187 added to existing stakes and 127 trimmed.
The largest buyer was Duquesne Family Office, opening a new position worth an estimated $108M. The largest seller was Citigroup, cutting an estimated $250M.
- 525 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2020, up from 458 in Q1 2020.
- Funds reported $9.39B of State Street SPDR S&P Biotech ETF stock for Q2 2020, up 26% quarter-over-quarter.
- 127 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2020 and 55 closed out, a net change of +72 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2020 was Duquesne Family Office, an estimated $108M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2020 was Citigroup, an estimated $250M sold.
Based on aggregated 13F filings for Q2 2020.